Skip to main content
. 2017 Nov 9;117(12):1846–1854. doi: 10.1038/bjc.2017.365

Figure 1.

Figure 1

The overall scheme of the MS-based pipeline for the development of novel pancreatic cancer biomarkers. The pipeline utilised a serial of MS-based methods such as iTRAQ-2DLC-MS/MS Strategy, 1D-targeted LC-MS/MS, P-MRM and SID MRM to construct a coherent, high-throughput and non-discriminatory pipeline with strict quantity control. The performance of newly developed biomarkers was statistically evaluated by ROC curves. ROC = receiver operation characteristic.